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Background: Perception of stigma was associated with low self-esteem, psychological 
problems, and decreased health-seeking behavior among patients with different neurological 
disorders. The purpose of this study was to assess stigmatization and its impact in patients 
with neuromyelitis optica spectrum disorder (NMOSD).
Methods: A non-interventional study was conducted at thirteen neuroimmunology clinics in 
Spain. Patients with a diagnosis of NMOSD (2015 Wingerchuk criteria) were included. The 
8-item Stigma Scale for Chronic Illness (SSCI-8), the Expanded Disability Status Scale 
(EDSS), the 29-item Multiple Sclerosis Impact Scale (MSIS-29), the Beck Depression 
Inventory-Fast Screen (BDI-FS), the MOS Pain Effects Scale (MOS-PES) and the Fatigue 
Impact Scale for Daily Use (D-FIS) were used to assess the perception of stigma, disability, 
quality of life, mood, pain, and fatigue, respectively. Associations between outcome mea-
sures were analyzed using Spearman’s rank correlation.
Results: Seventy-one patients were studied (mean age: 47.4 years ± 14.9, 81.7% female, 
mean time since disease onset: 9.9 years ± 8.1). The median EDSS score was 3.0 (inter-
quartile range 1.5, 4.5). Stigma prevalence was 61.4% (n=43). Thirty-one patients (43.6%) 
had depression. The SSCI-8 score showed a significant correlation with both physical 
(rho=0.576, p<0.0001) and psychological (rho=0.608, p<0.0001) MSIS-29 scales scores, 
EDSS score (rho=0.349, p=0.0033), BDI-FS score (rho= 0.613, p<0.0001), MOS-PES 
score (rho= 0.457, p<0.0001), and D-FIS score (rho=0.556, p<0.0001).
Conclusion: Stigma is a common phenomenon affecting over 6 out of 10 patients with 
NMOSD. Understanding stigma may be useful to develop educational strategies improving 
NMOSD knowledge.
Keywords: neuromyelitis optica spectrum disorder, stigma, quality of life, depression, 
patient-reported outcomes
Introduction
Neuromyelitis optica is a rare chronic inflammatory central nervous system disease 
characterized by monophasic or recurrent attacks of optic neuritis and transverse 
myelitis with poor or no recovery.1–3 The term neuromyelitis optica spectrum 
disorder (NMOSD) was established by an international panel in 2015 to enable 
early diagnosis in patients with or without aquaporin-4 antibodies.1 Motor and 
visual impairment, pain, and fatigue are among the most prevalent and debilitating 
symptoms.4,5 Residual disability usually limit daily function and independence over 
time.6,7
The definition of stigma traditionally refers to a feeling of disapproval that 
society has about something, especially when this is unfair.8 Perception of stigma 
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was a common phenomenon among people with neurolo-
gical disorders in a survey recently conducted by the 
European Federation of Neurological Associations.8 The 
impact of stigma has been documented across a number of 
neurological conditions contributing to lack of confidence, 
depression, anxiety, decreased health-seeking behavior, 
and unequal life opportunities.8–12
There is limited information available on the presence 
of stigma in patients with neuroinflammatory and demye-
linating disorders. Perception of stigma has been recently 
explored in multiple sclerosis (MS).13–17 Different studies 
showed a prevalence of perceived stigma of 20 and 80% in 
patients with relapsing-remitting and primary progressive 
MS, respectively.16,17 Even in patients with low physical 
disability, stigma was associated with poor quality of life, 
depression, and unemployment.15,17,18
Depression and psychological distress affect subjective 
well-being in patients with NMOSD.19–22 However, no 
studies have focused on stigma and NMOSD. The purpose 
of this study was to assess stigmatization and its impact 
on patients living with NMOSD.
Methods
A non-interventional, cross-sectional study was conducted 
at thirteen hospital-based neuroimmunology clinics in 
Spain (PERSPECTIVES-NMO study). Eligibility criteria 
included being at least 18 years old and having a diagnosis 
of NMOSD according to Wingerchuk 2015 criteria.23 This 
study was conducted in accordance with the Good Clinical 
Practice Guidelines of the International Conference on 
Harmonisation and with the ethical principles of the 
Declaration of Helsinki and was approved by the investi-
gational review board of Galicia (CEIm-G), Santiago de 
Compostela, Spain. Written informed consent was 
obtained from all participants.
Outcome Measures
The 8-item Stigma Scale for Chronic Illness (SSCI-8), the 
Expanded Disability Status Scale (EDSS), the 29-item 
Multiple Sclerosis Impact Scale (MSIS-29), the Beck 
Depression Inventory-Fast Screen (BDI-FS), the MOS 
Pain Effects Scale (MOS-PES) and the Fatigue Impact 
Scale for Daily Use (D-FIS) were used to assess the 
perception of stigma, disability, quality of life, mood, 
pain and fatigue, respectively.24–30
The SSCI-8 was developed to assess perceptions of 
stigma across different neurological conditions.24,25 It 
comprises eight items rated on a 5-point Likert scale 
from 1 (never) to 5 (always). Total scores range from 8 
to 40, with a cut-off score >8 indicating the presence of 
stigmatization. The MSIS-29 is a self-report question-
naire used to determine the impact of MS on health- 
related quality of life.27 It consists of two composite 
domains including physical (20 items) and psychologi-
cal impacts (9 items). Items are rated using four-point 
response categories: not at all, a little, moderately, and 
extremely. Scores on the physical and psychological 
impact subscales can range from 20 to 80 and from 9 
to 36, respectively. Higher scores indicate greater 
impact. The BDI-FS is a seven-item questionnaire asses-
sing the level of depressive symptoms.28 Responses to 
the items are provided on a four-point scale (no symp-
toms to severe symptoms) with total score ranging from 
0 to 21. Cut-off scores ≥4 and ≥9 are used to define the 
presence of depression and moderate-to-severe depres-
sion, respectively. The MOS-PES is a validated, six- 
item, self-report questionnaire to assess how pain and 
unpleasant sensations interfere with mood, ability to 
walk or move, sleep, work, recreation, and enjoyment 
of life.29 Total score ranges from 6 to 30, with higher 
scores indicating greater impact of pain. The D-FIS is 
an eight-item, self-report instrument designed to mea-
sure subjective daily experience of fatigue.30 Items are 
rated using a 5-point Likert scale from 1 (never) to 5 
(always). Higher scores indicate greater fatigue 
perception.
Statistical Analysis
Associations between outcome measures were analyzed 
using Spearman’s rank correlation. Logistic regression 
was used to assess the contribution of stigma to symptoms 
of depression (depressed, not depressed).
Results
A total of 71 patients were included in the study. The mean 
(± SD) age was 47.4 ± 14.9 years and 81.7% were female. 
The mean time since disease onset was 9.9 years ± 8.1 and 
the median EDSS score was 3.0 (interquartile range 1.5, 
4.5). Thirty-one patients (43.6%) had depression. 
Demographic and clinical characteristics of the sample 
are shown in Table 1.
The prevalence of stigma was 61.4% (95% CI 46.9, 
76.0 [n=43]) (Table 2). Feeling of being left out of things, 
followed by embarrassment because of physical limita-
tions and people avoided me because of my illness were 
the items with the highest impact.
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The SSCI-8 score showed a significant correlation 
with physical and psychological MSIS-29 scores 
(rho=0.576 and 0.608, p<0.0001, respectively), EDSS 
score (rho=0.349, p=0.0033), BDI-FS score (rho= 
0.613, p<0.0001), MOS-PES score (rho= 0.457, 
p<0.0001), and D-FIS score (rho=0.556, p<0.0001) 
(Table 3). Stigma was found to positively predict con-
current depression (OR=1.32; 95% CI: 1.13–1.55, 
p=0.0004).
Discussion
Little is known about the patient´s experience of living 
with NMOSD.31 Fear of disability and impaired activ-
ities of daily living were associated with uncertainty 
about the disease trajectory.31,32 Limitations in social 
activities and type of work were reported by most of 
522 patients participating in the US online community 
PatientsLikeMe.4 Somatic complaints and hopelessness 
were correlated with disease duration.22 Barzegar et al 
found that NMOSD patients had significantly worse 
quality of life compared with MS patients, with fatigue 
being the most important variable for predicting 
variance.33
The impact of stigma has been documented across 
a number of neurological disorders, especially 
Parkinson´s disease, epilepsy, and Alzheimer´s 
disease.8,10 Stigma was a common phenomenon in 
a survey with 1,373 patients with different neurological 
conditions from 37 countries.8 Lack of understanding 
was seen as the biggest cause of this, followed by mis-
conceptions about these disorders and their hidden nat-
ure. More than thirty percent of participants reported 
regularly being made to feel that their condition is their 
fault, over twenty percent felt that people avoid them 
often or always, and forty-five percent felt that they are 
regularly left out of things.
Perception of stigma in patients with NMOSD using 
standardized measures has not been previously explored. 
In our study, more than sixty percent of patients experi-
enced stigmatization. Stigma was found to have a strong 
negative correlation with physical and psychological qual-
ity of life.
There is scarce information regarding psychiatric 
comorbidities in patients with NMOSD. Based on 
a retrospective analysis of a US administrative claims data-
base, the prevalence of depression in patients with NMO 
(n=1,349) and highly active NMO (n=134; defined as at 
least two relapses within twelve months of the patient’s first 
NMO encounter in the database) was estimated at 17.9% 
and 25.4%, respectively.34 Fernandez et al found that ten 
patients with NMOSD (50%) had current depressive symp-
toms versus five (28%) patients with MS (p=0.16).35 Six 
(30%) patients with NMOSD versus only one (5.5%) 
patient with MS had attempted suicide at least once 
(p=0.05). Current suicide risk was high in patients with 
NMOSD (8, 40%) and moderate in patients with MS (4, 
22%). In our study, thirty-one patients (43.6%) had 
Table 1 Demographic and Clinical Characteristics
Total 
(n=71)
Age (years), mean ± SD 47.4 ± 14.9
Sex (female), n (%) 57 (80.3)
Education (university), n (%) 30 (42.2)
Living with family members or a partner, n (%) 63 (90)
Employment status (part or full-time employed), 
n (%)
21 (30)
Disease duration (years), mean ± SD 9.9 ± 8.1
Onset attack type, n (%)
Myelitis 34 (47.8)
Optic neuritis 27 (38)
Myelitis + optic neuritis 3 (4.2)
Other 7 (9.8)
Relapsing form, n (%) 59 (83.1)
Number of relapses since diagnosis, mean ± SD 2.9 ± 2.3
Number of relapses in the last year, mean ± SD 0.5 ± 0.9
Coexisting autoimmune disease, n (%) 21 (29.6)
EDSS score, median (IQR) 3.0 (1.5, 4.5)
Physical impact MSIS-29 score, mean ± SD 41.9 ± 16.7
Psychological impact MSIS-29 score, mean ± SD 20.9 ± 8.3
MOS-PES score, mean ± SD 13.9 ± 6.3
D-FIS score, mean ± SD 9.0 ± 8.3
BDI-FS score, mean ± SD 3.6 ± 3.4
Patients with depression, n (%) 31 (43.6)
Patients with moderate to severe depression, n (%) 8 (11.2)
Abbreviations: BDI-FS, Beck Depression Inventory-Fast Screen; D-FIS, Fatigue 
Impact Scale for Daily Use; EDSS, Expanded Disability Status Scale; IQR, interquar-
tile range; MOS-PES, Pain Effects Scale; MSIS-29, 29-item Multiple Sclerosis Impact 
Scale; SD, standard deviation.
Patient Preference and Adherence 2021:15                                                                               submit your manuscript | www.dovepress.com                                                                                                                                                                                                                       
DovePress                                                                                                                         
715


































































Powered by TCPDF (www.tcpdf.org)
depression. Differences regarding our findings could be 
based on cultural factors and the administration of different 
instruments to assess depressive symptoms across studies.
Stigma is a previously studied predictor of depres-
sion in patients with MS. Cadden et al and Pérez- 
Miralles et al assessed the association between stigma 
and depression in MS, concurrently and 
prospectively.15,36 A moderate bivariate correlation 
between stigma and depression measured at baseline 
and one year later was found in a survey with 5,413 
participants administered by the North American 
Research Committee on Multiple Sclerosis.15 Almost 
eighty percent of a sample of 55 patients with primary 
progressive MS reported some degree of stigmatization 
at baseline and one year later.16,36 Increased baseline 
SSCI-8 scores were associated with a higher risk of 
depression (OR=1.21, p=0.007) and moderate-to-severe 
depression (OR=1.37, p=0.003).36
Patients with rare diseases show even worse quality of 
life compared to the general population and people with 
common chronic diseases.37 A comprehensive disease 
information and educational efforts to achieve an adequate 
public knowledge of NMOSD may help in decreasing its 
stigma. The ultimate goal of all such initiatives should be 
to prevent the isolation of NMOSD patients and their 
families and to facilitate their social integration.
The relatively small sample size and cross-sectional 
design are the main limitations of this study. A causal 
relationship between stigma and depression cannot be 
established. We also cannot rule out the possibility that 
the perception of stigma was influenced by other fac-
tors that have not been analyzed in this study, such as 
Table 2 Perception of Stigma
n=70
SSCI-8 score, median (IQR) 10 (8.0, 15.0)
Stigma prevalence (total score >8), n (%) 43 (61.4)
Frequency, n (%)
SSCI-8 Items Never/Rarely Sometimes Often/Always
Because of my illness, some people seemed uncomfortable with me 60 (85.7) 9 (12.9) 1 (1.4)
Because of my illness, some people avoided me 57 (81.4) 8 (11.4) 5 (7.1)
Because of my illness, I felt left out of things 52 (74.3) 10 (14.3) 8 (11.4)
Because of my illness, people were unkind to me 61 (87.1) 7 (10) 2 (2.9)
Because of my illness, people avoided looking at me 62 (88.6) 6 (8.6) 2 (2.9)
I felt embarrassed about my illness 64 (91.4) 4 (5.7) 2 (2.9)
I felt embarrassed because of my physical limitations 52 (74.3) 13 (18.6) 5 (7.1)
Some people acted as though it was my fault I have this illness 61 (87.1) 5 (7.1) 4 (5.7)
Notes: ©2008–2019 David Cella on behalf of the National Institute for Neurological Disorders and Stroke (NINDS); some content used with permission of the PROMIS 
Health Organization. 
Abbreviations: SSCI-8, 8-item Stigma Scale for Chronic Illness; IQR, interquartile range.
Table 3 Correlations Between SSCI-8 and BDI-FS, MOS PES, D-FIS, and EDSS
Physical MSIS-29 Psychological 
MSIS-29
BDI-FS MOS-PES D-FIS EDSS
SSCI-8 r 0.576 0.608 0.613 0.457 0.556 0.349
p <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 0.0033
Abbreviations: BDI-FS, Beck Depression Inventory-Fast Screen; D-FIS, Fatigue Impact Scale for Daily Use; EDSS, Expanded Disability Status Scale; MOS-PES, Pain Effects 
Scale; MSIS-29, 29-item Multiple Sclerosis Impact Scale; r, Spearman’s rank correlation coefficient; SSCI-8, 8-item Stigma Scale for Chronic Illness.
submit your manuscript | www.dovepress.com                                                                                                                                                                                                                    
DovePress                                                                                                                                              
Patient Preference and Adherence 2021:15 716


































































Powered by TCPDF (www.tcpdf.org)
current immunosuppressant drugs and disease- 
modifying therapies for the management of NMOSD, 
impact of medical or psychological comorbid condi-
tions, or serologic status. However, the study sample 
was managed at 13 different hospitals throughout 
Spain, allowing results to be generalized to clinical 
practice.
Conclusion
Perception of stigma is a common phenomenon in 
NMOSD, even in a clinically stable population with low 
physical disability. Further studies with longitudinal fol-
low-up are needed to confirm the relationships between 
stigma and quality of life and mood and elucidate the 
underlying mechanisms.
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